Clearmind Medicine Inc. (NASDAQ: CMND) announced the publication of six new patents in Hong Kong on March 17 2026. The filings protect proprietary combination therapies that pair the company’s MEAI platform with six different psychedelic compounds—MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT—using Palmitoylethanolamide (PEA) sourced through its partner NeuroThera Labs.
The patents extend Clearmind’s intellectual‑property portfolio beyond its current focus on alcohol use disorder and depression. By securing protection for these MEAI‑PEA combinations, the company positions itself to pursue future clinical development and regulatory approvals across a broader range of indications, potentially enhancing safety and efficacy profiles for each compound. The move signals a strategic effort to broaden the therapeutic reach of the MEAI platform and to build a robust pipeline of next‑generation candidates designed to address unmet needs in mental health and beyond.
Management emphasized the importance of the IP expansion. CEO Adi Zuloff‑Shani said the company “continues to expand our global IP portfolio and takes steps forward in protecting our innovative approach to psychedelic‑based combination therapies.” He added that the partnership with NeuroThera Labs “provides a reliable source of PEA, enabling us to build a robust pipeline of next‑generation candidates.” The patents are an incremental milestone, but they lay the groundwork for future clinical programs and potential regulatory approvals that could ultimately translate into commercial opportunities.
While the patent publication does not represent an immediate revenue or regulatory breakthrough, it is a key step in Clearmind’s long‑term strategy. The expanded IP base strengthens the company’s competitive position, safeguards its research investments, and provides a foundation for future clinical and commercial development in multiple therapeutic areas.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.